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SUMMARY
Active-targeted delivery to lymph nodes represents a major advance toward more effective 
treatment of immune-mediated disease. The MECA79 antibody recognizes peripheral node 
address in molecules expressed by high endothelial venules of lymph nodes. By mimicking 
lymphocyte trafficking to the lymph nodes, we have engineered MECA79-coated microparticles 
containing an immunosuppressive medication, tacrolimus. Following intravenous administration, 
MECA79-bearing particles showed marked accumulation in the draining lymph nodes of 
transplanted animals. Using an allograft heart transplant model, we show that targeted lymph node 
delivery of microparticles containing tacrolimus can prolong heart allograft survival with 
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negligible changes in tacrolimus serum level. Using MECA79 conjugation, we have demonstrated 
targeted delivery of tacrolimus to the lymph nodes following systemic administration, with the 
capacity for immune modulation in vivo.
Graphical Abstract
INTRODUCTION
Lymph nodes (LNs) function as a primary site for the priming and activation of immune 
cells in a wide variety of immune-mediated diseases (Goldstein et al., 2003; von Andrian 
and Mempel, 2003). Recognition of non-self alloantigens occurs in the draining lymph 
nodes (DLNs), resulting in the formation of alloreactive T cells and subsequent transplant 
rejection (Lakkis et al., 2000). Similarly, pancreatic lymph nodes play a key role in the 
formation of autoreactive T cells and in the pathogenesis of type 1 diabetes (Park and 
Kupper, 2015). LNs are also common sites for primary lymphoproliferative malignancies 
and metastatic niches (Stacker et al., 2014). Therefore, developing targeted delivery of drugs 
to the LNs represents a significant milestone and holds the potential to increase the efficacy 
of immune and cancer therapies. Targeted drug delivery also allows reduced systemic dosing 
with corresponding reductions in off-target toxicities.
The optimal, most clinically applicable drug delivery system would involve intravenous 
administration of an agent that would then localize to and act at a chosen site. In recent 
years, innovative approaches have been developed to target drugs specifically to the 
lymphoid system (Dane et al., 2011; Hunter et al., 2014; Jewell et al., 2011; Liu et al., 2014; 
Reddy et al., 2007; Yeste et al., 2012). Despite these advances, a LN-targeted drug delivery 
system using the intravenous route remains to be fully developed. Successful targeted 
delivery of immunoregulatory molecules or chemotherapy drugs to the LNs following 
intravenous administration holds immense potential for application in the treatment of a 
wide variety of immune-mediated diseases and cancers.
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The primary concept behind our microparticle (MP) delivery system essentially shadows the 
footsteps of naive T cells and central memory cells, which circulate between the blood and 
LNs for antigen surveillance (von Andrian and Mackay, 2000). The trafficking of 
lymphocytes from the circulation to LNs is initiated by a highly regulated process referred to 
as tethering, which is controlled by selectin molecules (Somers et al., 2000). L-selectin, 
expressed on leukocytes, recognizes sulfated sialyl-LewisX-like sugars, called peripheral 
node addressins (PNAds), which are expressed by high endothelial venules (HEVs) in the 
LNs (Carlow et al., 2009; Sperandio et al., 2009; von Andrian and Mackay, 2000). Through 
this interaction, L-selectin plays a key role in the continuous homing of naive T cells to the 
LNs, where they encounter antigens presented by antigen-presenting cells. The monoclonal 
antibody (Ab) MECA79 binds PNAd, and, utilizing this interaction, we have successfully 
designed an innovative LN-targeted drug delivery strategy. Our platform consists of 
MECA79-bearing particles with the capacity to load and release tacrolimus (TAC). TAC is 
the most commonly clinically used immunosuppressant post-transplantation, and by 
directing this agent to the site of T cell activation in the lymph node, we have developed a 
functional, clinically relevant approach. Using a cardiac transplant model, we show proof of 
concept of the targeted delivery of MECA79-coated particles to DLNs, achieving immune 
modulation in vivo and resulting in improved heart allograft survival with negligible levels 
of TAC in peripheral blood.
RESULTS
Formulation of MP-TAC-MECA79
TAC was first conjugated to the poly(lactide) (PLA) polymer chain through TAC-initiated, 
controlled ring-opening polymerization (ROP) of lactide (LA) mediated by (BDI-
EI)ZnN(TMS)2, an organozinc catalyst (Figure 1; Chamberlain et al., 2001; Tong and 
Cheng, 2008). After TAC was mixed with 1.0 equivalent (BDI-EI)ZnN(TMS)2, the in situ-
formed (BDI-EI)Zn-TAC complex (Figure 1A) initiated and completed the polymerization 
of LA at room temperature (Figure 1B), resulting in TAC-PLA conjugate with a precisely 
controlled structure and molecular weight. The loading of TAC can thus be precisely 
controlled by adjusting monomer/initiator (LA/TAC) ratios. At the LA/TAC molar ratio of 
25 (molar ratio, on a lactide basis), the drug loading of TAC-PLA conjugates can be as high 
as 18.3% with nearly 100% loading efficiency. After polymerization, TAC is covalently 
conjugated to the terminals of PLA through a hydrolysable ester linker, evidenced by the end 
group analysis via MALDI-TOF mass spectrometry (MS) (Figure 1C).
MECA79 monoclonal antibody-modified, TAC-loaded microparticles (MP-TAC-MECA79) 
were then prepared using the double emulsion method (Figure 1A). The synthesized TAC-
PLA was first mixed with poly(ethylene glycol)-b-poly(lactic-co-glycolic acid) (PEG-
PLGA) and PEG-PLA-carboxylic acid (COOH) and then emulsified in poly(vinyl alcohol) 
(PVA) solution using sonication and homogenization. The formed MPs with carboxyl groups 
were further conjugated with protein G by a coupling reaction and then bonded with 
MECA79. The resulting MPs had sizes of 2.30 ± 0.14 µm in diameter by dynamic light 
scattering (DLS) measurement (Figure 2A) and confirmed by scanning electron microscope 
imaging (Figure 2B). Non-modified MP-TAC was formulated by using the same method and 
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showed similar physicochemical properties as MP-TAC-MECA79 (Figure 2C). To facilitate 
potential clinical translation, it is desirable to formulate particles in solid form to minimize 
drug release prior to use. Thus, we attempted to use BSA as the lyoprotectant of MP solid 
formulation. The data in Figure 2D demonstrate that BSA could effectively protect the solid 
form of MP-TAC-MECA79 and MP-TAC from aggregation after reconstitution in water.
Immunosuppressive Capacity of MP-TAC-MECA79 In Vitro
We then examined the retention and release of TAC from MP-TAC-MECA79 by testing its 
ability to suppress T cell proliferation in vitro. MP-TAC-MECA79 and an equivalent dose of 
free TAC were added in a dose-dependent fashion to an anti-CD3/CD28 T cell stimulation 
assay. As shown in Figures 3A and 3B, MP-TAC-MECA79 and free TAC suppressed T cell 
proliferation, as measured by thymidine incorporation, in a dose-dependent fashion, starting 
at 0.5 ng/ml TAC-equivalent concentration (p < 0.05). Furthermore, MP-TAC-MECA79 
suppressed inflammatory cytokine (interleukin-2 [IL-2], interferon γ [IFNγ], IL6, and IL17) 
production by T cells, as measured by Luminex analysis of the T cell culture supernatant 
(Figures 3C–3F). However, MP-MECA79 particles with no TAC (MP-MECA79 particles 
dose-equivalent to MP-TAC-MECA79 at 5 ng/ml TAC equivalent) did not suppress T cell 
proliferation when added to the anti-CD3/ CD28 T cell stimulation assay (174.276 3 103 
± 2.227 × 103 versus 155.587 × 103 ± 21.089 × 103, respectively; p = 0.22), demonstrating 
the requirement for the immunosuppressive agent tacrolimus to prevent T cell activation.
Targeted Delivery of MP-TAC-MECA79 to Draining Lymphoid Tissues Post-transplantation
PNAds are expressed on the vascular endothelium of peripheral LNs and are induced on 
venules at sites of chronic inflammation, including transplanted organs undergoing rejection 
(Baddoura et al., 2005; Michie et al., 1993; Xu et al., 2003; Yin et al., 2011). We first 
investigated the expression of PNAd in DLNs using a murine skin transplant model, which 
has a well-defined lymphatic drainage to the DLNs. C57BL/6 recipients were transplanted 
with full-thickness skin grafts taken from either C57BL/6 donors (syngeneic) or BALB/c 
donors (allogeneic), as described previously (Yuan et al., 2003). DLNs were retrieved from 
transplanted mice on day 7 post-transplantation. We then examined the level and pattern of 
expression of PNAd in DLNs by western blot and immunohistochemistry. As shown in 
Figure 4A, DLNs of allogeneic transplants had a significant increase in PNAd expression 
compared with syngeneic transplants. Following the normalization of ERK1/2 as the loading 
control, our densitometric analysis indicated a 4-fold increase in allogeneic hosts compared 
with syngeneic ones (Figure 4A; ***p < 0.001, n = 3 mice/group). Similarly, DLNs from 
allogeneic recipients showed a marked increase in PNAd-expressing vasculature compared 
with the non-draining LNs (Figures 4B and 4C).
We then tested the efficacy of preferential trafficking of MECA79-coated particles to DLNs 
following transplantation. We first synthesized TAC-containing particles coated with 
MECA79 (MP-TAC-MECA79) and non-coated (MP-TAC). Both sets of particles were 
labeled with rhodamine to monitor their trafficking (MP-Rhd-MECA79 and MP-Rhd, 
respectively) (Table S1). On day 7 after transplantation of an allogeneic skin graft, recipient 
mice were injected with either MP-Rhd-MECA79 or MP-Rhd via the tail vein. We harvested 
the DLNs 24 hr after injection and quantified the rhodamine-labeled particles using 
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immunohistochemistry. LN sections were stained for nuclei with DAPI (blue) and PNAd 
(green). These sections were examined for the presence of red MP-Rhd and MP-Rhd-
MECA79 particles (rhodamine-loaded), and particles were counted per high-power field 
(403 objective). As shown in Figures 4D and 4E, immunohistochemistry staining showed a 
much higher number of particles in the DLNs of animals injected with MP-Rhd-MECA79 
(red dots, Figure 4D, right) compared with MP-Rhd (Figure 4D, left). The MP-Rhd-
MECA79 was localized adjacent to the PNAd-positive vessels and surrounding cells (Figure 
4D, right).
Next, draining and non-draining LNs of skin allograft recipients treated with MP-Rhd-
MECA79 were examined by two-photon microscopy. As shown in Figure 4F, a higher 
density of PNAd-positive vessels (green) was again observed in DLNs compared with non-
draining LNs in addition to a higher number of MP-Rhd-MECA79 (red). Optical sections of 
the tissue imaged by two-photon microscopy were compiled into a three-dimensional 
volume (Movie S1).
A lower level of PNAd expression was observed in the non-draining LNs of transplanted 
mice compared with DLNs (Figures 4B and 4C). As predicted by this pattern of PNAd 
expression, no difference was observed in the trafficking of MP-Rhd-MECA79 and MP-Rhd 
particles to the non-draining LNs of transplant recipients, as assessed by flow cytometry 
(Figure S1A and S1C) or by immunohistochemistry (data not shown).
Spleens of transplanted mice were also analyzed by immunohistochemistry after intravenous 
injection of the different particles. No splenic PNAd staining was detected, as shown in 
Figure S2A. As expected, no difference in trafficking of MP-Rhd-MECA and MP-Rhd 
particles to the spleens of transplanted mice was detected by flow cytometry analysis, as 
shown in Figure S2B and S2C (n = 4 mice/group).
Functional Role of MECA79 in Targeted Trafficking of MP-TAC-MECA79 Particles
To show the functional role of the MECA79 Ab in mediating the preferential trafficking of 
MP-Rhd-MECA79 to the DLNs, on day 7 after transplantation, skin allograft recipients 
were injected with anti-PNAd blocking antibody (MECA79, 200 µg/mouse) 1 hr before 
injection of MP-Rhd-MECA79 or MP-Rhd. DLNs were isolated, and cell suspensions were 
analyzed by flow cytometry to detect the rhodamine-labeled particles. In the absence of 
PNAd blockade, significantly more of rhodamine-labeled particles were detected by flow 
cytometry in the inguinal DLNs of mice injected with MP-Rhd-MECA79 compared with 
MP-Rhd (1,527 ± 480 versus 185.8 ± 57 particles, respectively; p < 0.05; n = 3–4 mice/
group) (Figures 5A and 5C). Blocking PNAd reduced the trafficking of MP-Rhd-MECA79 
to the DLNs (1,527 ± 480 versus 98 ± 56 particles, respectively; p < 0.05; n = 3–4 mice/ 
group). However, PNAd blockade did not affect the observed low levels of MP-Rhd 
trafficking to the DLNs (185.8 ± 57 versus 193 ± 71 particles, respectively; p = not 
significant [ns]; n = 3–4 mice/group) (Figures 5B and 5C). This shows that the preferential 
trafficking of MP-Rhd-MECA79 to DLNs after transplantation is mediated by the binding of 
MECA79 to LN-expressed PNAd.
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To assess the accumulation of particles in other lymphoid tissues, non-draining LNs 
(pancreatic LNs) were isolated, and cell suspensions were analyzed by flow cytometry to 
detect rhoda-mine-labeled particles under PNAd blockade. The presence or absence of 
PNAd blockade had no effect on the accumulation of intravenously injected MP-Rhd-
MECA79 or MP-Rhd in non-draining lymph nodes (Figure S1A–S1C). After allogeneic 
transplantation, draining lymph nodes enlarge markedly because of allostimulated 
lymphocyte proliferation. As anticipated, more than 10-fold more cells were isolated from 
DLNs than non-draining lymph nodes, as measured by flow cytometry (Figure S1D). This 
effect leads to the observed substantial differences in absolute cell count despite a similar 
overall percentage, as seen by flow cytometry analysis.
Therapeutic Efficacy of MP-TAC-MECA79 in Prolonging Heart Allograft Survival
To examine the therapeutic efficacy of MP-TAC-MECA79 in a more clinically applicable 
solid organ transplant model, we next analyzed the expression of PNAd in the draining and 
non-draining LNs of heart transplant recipients. As shown in Figure 6A, 
immunohistochemistry analysis of DLNs of mice transplanted with heart allografts showed a 
significant increase in PNAd expression compared with non-draining LNs on day 7 post-
transplantation. Furthermore, a newly formed network of PNAd-positive cells from much 
larger vessels in the DLNs was also observed (arrows). To study allograft survival, C57BL/6 
recipients of BALB/c hearts were injected daily with MP-TAC-MECA79, MP-TAC, or free 
TAC (each dosed at 1 mg/kg TAC equivalent) for 6 consecutive days. Given that high serum 
levels of TAC cause allograft vascular injury and toxicity, we were interested in the effect of 
our treatment particles on systemic TAC exposure. To assess this, we measured the blood 
levels of TAC in transplanted mice on day 3 after transplantation (Azzi et al., 2010; 
Chapman and Nankivell, 2006; Vercauteren et al., 1998; Wong et al., 2005). As shown in 
Figure 6B, the TAC peak level 2 hr after injection of the compounds was significantly lower 
in the MP-TAC-MECA79 compared with the free TAC group (2.63 ± 0.56 versus 37.00 
± 2.62, respectively; p < 0,05; n = 3 mice/group). Furthermore, as shown in Figure 6C, the 
TAC trough level 24 hr after injection was also significantly lower for MP-TAC-MECA79 
compared with free TAC (2.45 ± 0.05 versus 0.60 ± 0.05, respectively; p < 0.05; n = 3 mice/
group). No significant difference was seen in the peak and trough levels of TAC in MP-TAC-
MECA79 and MP-TAC (Figures 6B and 6C).
Interestingly, despite a more than 15-fold decrease in the peak level of TAC, transplanted 
mice treated with MP-TAC-MECA79 showed a significant prolongation of heart allograft 
survival compared with control groups (median survival 11 days versus 7 days, respectively; 
p <0.05; n=4–5/group). Furthermore, heart allograft recipients treated with MP-MECA79 
(without TAC) or MP (without TAC) showed no increase in allograft survival compared with 
untreated mice or mice treated with MP-TAC or free TAC (median survival 7 days, p = ns, n 
= 4–5/group) (Figure 6D). These data confirm that the allograft-prolonging effect is 
dependent on the presence of TAC within microparticles delivered to DLNs.
Finally, we measured the suppressive effects of MP-TAC-MECA79 on activated T cells in 
the DLNs of treated animals. Activated alloreactive T cells are identified by their 
upregulated expression of CD44 and downregulation of CD62L. These 
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CD4+CD62LlowCD44high T cells only require low levels of antigenic stimulation to undergo 
substantial proliferation and are the effector population in allograft rejection (Azzi et al., 
2015; Jones et al., 1999; Krupnick et al., 2014; Vergani et al., 2013). On day 7, mice were 
harvested, and the DLNs of heart allograft recipients were analyzed by flow cytometry. CD4 
effector T cells (CD4+CD62LlowCD44high) were significantly reduced in mice treated with 
MP-TAC-MECA79 compared with the MP-TAC- and free TAC-treated groups (271.0 
± 65.00 versus 1,686 ± 361.9 versus 4,508 ± 735.5, respectively; p < 0.05; n = 3 mice/group) 
(Figures 6E and 6F).
DISCUSSION
The potential for targeted drug delivery to improve the efficacy/ safety ratio of existing drugs 
has fueled considerable research and prompted clinicians to apply this technology across a 
range of clinical settings (Wagner et al., 2006). However, targeted delivery to specific tissue 
sites following systemic administration remains challenging (Mitragotri et al., 2014). The 
primary focus of our work has been to achieve active-targeted delivery to the HEVs of LNs 
via an intravenous route. The DLN is a primary site of alloreactive and autoreactive T cell 
activation and therefore plays a central role in the pathogenesis of transplant rejection and 
autoimmune diseases, rendering this site an attractive target for drug delivery (Lakkis and 
Sayegh, 2003; Park and Kupper, 2015).
Solid organ transplantation is a life-saving procedure for end organ failure, but its success is 
blunted by the limitations of currently available immunosuppressive agents. Calcineurin 
inhibitors such as TAC are the cornerstone of immunosuppressive therapy after 
transplantation. However, TAC-induced organ toxicity, cardiovascular events, and 
malignancies are major causes of graft loss and mortality (Halloran, 2004). There have been 
numerous sizable clinical trials targeted at sparing, minimizing, or withdrawing calcineurin 
inhibitors in an attempt to reduce their toxicity. However, these trials have faced significant 
challenges, including decreased efficacy, persistent toxicities, and new toxicities caused by 
the replacement drug (Flechner et al., 2008; Haller and Oberbauer, 2009). Therefore, 
developing innovative strategies to improve the ratio of efficacy and toxicity of 
immunosuppressive therapies remains one of the greatest challenges in the treatment of 
immune-mediated diseases, including transplant rejection (Azzi et al., 2013). Given that 
nano-therapeutics are already in clinical use, this platform has the potential to tackle one of 
the most immediate clinical problems in transplantation.
Migration of naive lymphocytes to the LNs is initiated by the interaction of L-selectin 
expressed on lymphocytes with a series of glycoprotein ligands expressed by HEVs in the 
lymph nodes, referred to as PNAd molecules (Berg et al., 1992; Butcher and Picker, 1996; 
Campbell et al., 2003; Hänninen et al., 1996; Michie et al., 1993; Streeter et al., 1988; van 
Zante et al., 2003). Following transplantation, we observed increased PNAd expression in 
DLNs. PNAds are recognized by the MECA79 monoclonal antibody, and, by engineering 
MECA79-coated microparticles, we sought to exploit the role of PNAd in lymphocyte 
trafficking in a model of transplant rejection. Our data indicate that MECA79 surface-
bearing particles showed significantly greater trafficking to DLNs compared with control 
particles. We demonstrated significantly less accumulation of microparticles in non-draining 
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LNs where PNAd expression was unchanged. To show the functionality of MECA79, we 
blocked the interaction of MECA79 with PNAd prior to injection of particles, which 
abrogated targeted delivery to DLNs. Furthermore, MECA79-conjugated and -non-
conjugated particles traffic equally to the spleen, which does not express PNAd. These data 
indicate that the marked increase in PNAd expression in the DLNs following transplantation 
drives the increased trafficking of MECA79-bearing particles to that site. This suggests that 
our targeted delivery system should be applicable to other disease states where PNAd is 
upregulated, highlighting its potential to treat a broad spectrum of diseases.
Although a skin transplant model with clear lymphatic drainage to DLNs was used to show 
proof of concept of targeted delivery, we then used a heart transplant model as a clinically 
applicable model to show proof of concept of efficacy. We used TAC-loaded particles 
because of TAC’s importance as a clinical agent in the prevention of transplant rejection. 
Within the lymph node, MECA79-conjugated MPs with TAC reduced T cell proliferation, as 
evidenced by the marked reduction in CD44highCD62Llow activated alloreactive T cells in 
the DLNs of treated animals. At the molecular level, TAC inhibits calcineurin, which is 
responsible for the dephosphorylation of nuclear factor of activated T cells (NFAT). NFAT 
increases the activity of IL-2 and other cytokine-encoding genes (Azzi et al., 2013; Kolata, 
1983; Zhang et al., 1996). Blockade of this pathway therefore prevents T cell activation and 
proliferation. Furthermore, peak TAC levels are closely correlated with the development of 
toxicities, and serum drug levels are readily quantifiable, allowing us to demonstrate both 
the efficacy of this directed therapy but also its considerable potential to decrease unwanted 
effects by minimizing total drug exposure. Indeed, treatment of allograft recipients with MP-
TAC-MECA79 induced higher allograft survival compared with the other groups with 
markedly lower levels of TAC (>15-fold less) in peripheral blood. It is important to note that 
the extent of prolongation of graft survival reported here is based on using a single 
immunosuppressive agent, TAC, which does not induce tolerance on its own in any 
transplant setting. Given that we used a stringent model of alloreactivity with a complete 
major histocompatibility complex (MHC) mismatch and achieved negligible TAC levels in 
peripheral blood, the observed prolongation of heart allograft survival represents a major 
immunomodulatory effect in vivo. These findings show the ability of this platform to 
achieve a greater degree of therapeutic efficacy while holding the potential to improve the 
side effect profile through reduced systemic drug exposure.
L-selectin itself is a rolling receptor because of its very short bonding time and inefficient 
accumulation. We chose a MECA79-based platform because MECA79 is likely to have 
broader coverage and also carries the advantage of blocking lymphocyte trafficking. MP-
MECA79 without TAC showed no prolongation of graft survival, indicating that impaired 
lymphocyte homing because of PNAd blockade is unlikely to be a significant contributor to 
the observed graft survival. Furthermore, of all experimental groups, only MP-TAC-
MECA79 showed prolongation of allograft survival, indicating dependence upon the local 
activity of TAC within the LNs to mediate this effect. With standard tools, it is impractical to 
compartmentalize TAC in the DLNs. In future studies, we foresee using evolving cutting 
edge matrix laser dissection methods, which may allow better analysis of the kinetics of 
targeted drugs in a very small environment such as the LNs.
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There have been major efforts to build lymphatic delivery platforms for a wide variety of 
therapeutic and diagnostic applications. Many of these strategies use lymphatic absorption 
with promising results (Cho and Lee, 2014; Dane et al., 2011; Hunter et al., 2014; Jewell et 
al., 2011; Liu et al., 2014; Reddy et al., 2007; Yeste et al., 2012; Zhang and Lu, 2014). Our 
strategy, which targets HEVs via the intravenous route, could effectively complement these 
approaches and/or expand the therapeutic applications when targeting the lymphatic system.
The PNAd/L-selectin pathway has also been shown to regulate lymphocyte trafficking to 
lymphoid tissue in non-obese diabetic (NOD) mice (Xu et al., 2010). PNAd is upregulated 
on the venous endothelium in inflammatory states and autoimmune diseases such as type 1 
diabetes mellitus (Michie et al., 1993; Mikulowska-Mennis et al., 2001; Penaranda et al., 
2010). Therefore, it is likely that increased PNAd expression, similar to what we describe 
after transplantation, also occurs in the DLNs of tissues affected by autoimmunity.
Our drug delivery platform carries considerable inherent plasticity and could be re-
engineered to incorporate a wide variety of immunoregulatory molecules and antibodies. 
Therefore, we envisage that this platform has the potential to deliver combinatorial therapies 
not only for the purpose of suppressing alloor auto-reactive T cells but also promoting 
regulatory T cells (Ochando et al., 2005). A number of studies have shown that particles in 
the micrometer range (such as ours, at 2–5 µm) accumulate readily within the lung capillary 
bed and are removed by the macrophage phagocytic system (MPS) of the spleen and liver 
(Blanco et al., 2015; Cabral et al., 2011; Kobayashi et al., 2014; Nel et al., 2009; Oussoren 
and Storm, 2001). One of our central future goals is to further improve the efficacy of this 
platform by designing smaller-size particles. Reducing the size of particles (~100 nm) would 
allow them to evade lung entrapment and avoid rapid clearance by the MPS, leading to a 
longer circulation time and therefore increased delivery to LNs (Blanco et al., 2015). Last, 
the use of protein G and BSA to coat particles may be associated with an adverse immune 
reaction when nano-formulations are used in humans. In the future, we aim to test other 
coating materials, such as branched PEG to increase PEG density on surface, zwitterionic 
materials that have shown interesting stealth effects, or human serum albumin. These 
materials will address the immunogenic effect of BSA and allow the conjugation of 
MECA79 (without protein G) with the surface coating.
Here we describe a drug delivery platform with the capacity to deliver drugs to the LNs in a 
targeted manner after intravenous administration, leading to in vivo immunomodulation with 
minimal detectable peripheral drug levels. With the capability to deliver a range of 
immunoregulatory molecules, this system has the potential to increase the efficacy of 
treatment for autoimmune disorders (i.e., delivering immunomodulatory molecules to the 
pancreatic lymph nodes for type 1 diabetes) (Park and Kupper, 2015) and a range of cancer 
therapies where the LN is an important site for disease progression (Stacker et al., 2014).
EXPERIMENTAL PROCEDURES
General
D,L-Lactide was purchased from TCI America, recrystallized three times in toluene, and 
stored at −30°C in a glove box prior to use. (BDI-EI)ZnN(TMS)2 was prepared by following 
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reported procedures (Chamberlain et al., 2001). FK506 (TAC) (Cayman Chemical) was used 
as received. All other chemicals were obtained from Sigma-Aldrich and used as received 
unless otherwise noted. High-performance liquid chromatography (HPLC) analysis was 
performed on a System Gold system (Beckman Coulter). Infrared spectra were recorded on 
a PerkinElmer 100 serial Fourier transform infrared spectroscopy (FT-IR) 
spectrophotometer. MALDI-TOF MS spectra were collected on an Applied Biosystems 
Voyager-DETM STR system. The sizes and polydispersities of MPs were determined on a 
ZetaPALS dynamic light-scattering detector. The ζ potential of freshly prepared MPs was 
evaluated by Malvern Zetasizer. Lyophilization of MPs was completed on a benchtop 
lyophilizer (Freezone 2.5, Fisher Scientific. The sizes of MPs were characterized on a 
Hitachi S4700 high resolution scanning electron microscope.
Synthesis and Characterization of FK506-PLA Polymer Conjugate
(BDI-EI)ZnN(TMS)2 (6.5 mg, 0.01 mmol) was dissolved in anhydrous tetrahy-drofuran 
(THF) (500 µl). The solution was added to a vial containing TAC (8.0 mg, 0.01 mmol), and 
the mixture was completely stirred for 15 min. LA (36.0 mg, 0.25 mmol) was dissolved in a 
vial containing THF (800 µl) and added to the mixture of TAC/(BDI-EI)ZnN(TMS)2. FT-IR 
was used to follow the conversation of LA in the polymerization solution by monitoring the 
intensity of the lactone band at 1772 cm−1. After LA was completely consumed, the 
polymerization was quenched by ice-cold methanol (20 µl). Then the polymer conjugate 
TAC-PLA was precipitated with ether (50 ml) and dried under a vacuum. The resulting 
TAC-PLA was denoted as TAC-PLAn, where n is the monomer/initiator (LA/TAC) molar 
ratio. The polymer was then analyzed by MALDI-TOF mass spectrometry.
Preparation of MP-TAC-MECA79
TAC-MPs were prepared using the water-in-oil-in-water (W/O/W) solvent evaporation 
procedure (also known as the double emulsion method). In brief, 50 µl aqueous solution was 
emulsified in a mix of 1 ml solution of PEG-PLGA (30 mg), PLA-PEG-COOH (6 mg), and 
TAC-PLA (30 mg containing 5.5 mg TAC) in dichloromethane (DCM) using a probe 
sonicator (Sonic & Materials) at 10 W (1%) for 15–30 s. The emulsion was then poured into 
50 ml of aqueous PVA (1%) aqueous solution, and the mixture was homogenized for 1 min 
at 8,000 rpm. The resulting emulsion was poured into 300 ml of aqueous PVA (0.3%) with 
gentle stirring, after which the organic solvent was evaporated by stirring at room 
temperature (RT) for 3 hr in the hood. The MPs were isolated by centrifugation at 10,000 
rpm for 20–30 min, washed with distilled (DI) water (20 ml), and dispersed in DI water (20 
ml). To modify the MP surface with MECA79 Ab, 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (10 mg) and N-hydroxysuccinimide (6 mg) were added 
to 20 ml MP solution (66 mg), followed by addition of protein G (0.5 mg in 40 µl DI water) 
after 10 min (Tong et al., 2010). The mixture reacted overnight at RT. The MP was then 
centrifuged at 10,000 rpm for 20 min, washed with DI water (20 ml), and dispersed in 20 ml 
DI water. The concentration of MECA79 Ab is 200 µg/ml. 50 µl of Ab solution was added 
into MP solution.
Azzi et al. Page 10
Cell Rep. Author manuscript; available in PMC 2017 May 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
The MP was then washed as described above and dispersed in DI water for use. The MPs 
without added IgM during the formulation were used as a control (MP-TAC). The MP size 
was determined by DLS and scanning electron microscopy.
For the preparation of Rhd-labeled MP-Rhd or MP-Rhd-MECA79, Rhd-PLA (30 mg) was 
mixed with the DCM solution of the PEG-PLGA and PLA-PEG-COOH polymer for 
subsequent double emulsion. The resulting fluorescent MPs were collected and washed 
similarly.
ξ Potential Measurements
The ξ potential of the MPs was determined with a Malvern Zetasizer. The freshly prepared 
MPs were dispersed in DI water to a concentration of 0.5 mg/ml.
Lyophilization of MPs in the Presence of BSA as a Lyoprotectant
BSA as a lyoprotectant was added to the concentrated MP suspension at a mass ratio of 
BSA/MP =10/1. The solution was then lyophilized to dry powder, which was stored at 
−20°C prior to use. The MPs were reconstituted with water and stirred for 5 min. The sizes 
of the resulting NPs were analyzed by DLS.
Mice
C57BL/6 and BALB/c(H-2d) mice were obtained from The Jackson Laboratory. All animals 
were used at 6–10 weeks of age (20–25 g) and housed in accordance with institutional and 
NIH guidelines. The Harvard Medical School Animal Management Committee approved all 
animal experiments.
Murine Skin Transplantation
Full-thickness trunk skin grafts (1 cm2) harvested from BALB/c donors were transplanted 
onto the flanks of C57BL/6 recipient mice, sutured with 6.0 silk, and secured with dry gauze 
and a bandage for 7 days. The draining LN harvested was the inguinal LN. To count the 
absolute number of Rd-labeled particles in LNs, LN samples were prepared into single-cell 
suspension, and the cell number was enumerated by flow cytometry. The percentage of Rd-
labeled events was measured by flow cytometry. This percentage was then applied to the 
count measured from the LN single-cell suspension, and the absolute count for Rd-labeled 
events was calculated.
Murine Cardiac Transplantation
Vascularized intra-abdominal heterotopic transplantation of cardiac allografts was performed 
using microsurgical techniques (Corry, 1973). Graft survival was assessed by daily 
palpation. Rejection was defined as complete cessation of cardiac contractility as determined 
by direct visualization and was confirmed by histological examination. Para-aortic lymph 
nodes from the host were harvested as draining LNs of the heart allografts.
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Immunohistochemistry
Lymph node, spleen, lung, and liver tissue samples were snap-frozen with optical cutting 
temperature compound (OCT) in liquid nitrogen and stored at −70°C until use. Frozen 
sections (8 µm) were prepared using a cryostat and immediately used or stored at −70°C 
until use. The sections were fixed with ice-cold acetone for 1 min, washed with PBS for 10 
min, and blocked for 30 min with 3% BSA-PBS as a blocking solution. The anti-HEV 
marker PNAd-Alexa Fluor 488 and anti-B cell B220-APC antibodies (eBioscience) were 
diluted (1:200) in the blocking solution. Sections were incubated with these antibodies for 1 
hr at room temperature or overnight at 4°C. Sections were washed with PBS. After washing, 
a coverslip was placed with Vectorshield (Vector Laboratories) mounting medium containing 
DAPI, and sections were analyzed using a Nikon C1 laser confocal microscope. For negative 
controls, the sections were stained by omitting the primary antibody.
Two-Photon Microscopy—Draining and non-draining LNs from recipients of an 
allogeneic skin graft were frozen in OCT, and 200-µm sections were generated. Optical 
sections of the tissue were imaged by two-photon microscopy and compiled into a three-
dimensional volume.
Western Blot
Lymph nodes were lysed in ice-cold lysis buffer, and the protein concentration of cell lysates 
was measured using the Bradford (Bio-Rad) assay. Equal amounts of protein were separated 
by 10% SDS-PAGE and transferred to a nitrocellulose membrane. The membranes were 
blocked with 5% non-fat milk in Tris-buffered saline (TBS)-0.05%Tween (TBST) and 
incubated overnight at 4°C with the following primary antibodies: MECA79 (anti-PNAd, 
BD Biosciences) and ERK1 (Santa Cruz Biotechnology). The blots were washed and 
developed with SuperSignal West Pico or West Dura chemiluminescent substrates (Thermo 
Scientific) using a Bio-Rad ChemiDoc imaging system, and the bands were quantified using 
Image Lab (Bio-Rad) software. MECA79 is a carbohydrate epitope found on a group of 
sulfation-decorated sialomucins, including sulfated ligands for CD62L (CD34, GlyCAM-1, 
Sgp200, and a subset of MAdCAM-1). This set of antigens has been referred to as PNAd 
with a molecular mass of 50–250 kD. Therefore, in the western blot, bands of multiple 
molecular weights were detected.
Flow Cytometric Analysis
Cells recovered from spleens and peripheral lymphoid tissues were analyzed by flow 
cytometry with a FACS Canto-II flow cytometer (BD Biosciences) and analyzed using 
FlowJo software version 9.3.2 (Tree Star).
Anti-CD3/CD28 Stimulation Assay
100 µl of anti-CD3 Ab diluted in PBS (1 µg/ml, BD Biosciences) was added to each well of 
a 96-well flat-bottom plate, placed at 37°C for 4 hr, and then washed twice with PBS. 
Soluble anti-CD28 Ab (1 µg/ml, BD Biosciences) was added to each well in the presence of 
5 × 105 splenocytes and an increasing concentration of MP-TAC-MECA79. Cultures were 
pulsed with triturated thymidine 72 hr after stimulation to assess cell proliferation.
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Luminex Assay—A 21-plex cytokine kit (Millipore) was used according to the 
manufacturer’s instructions.
Statistics—Kaplan-Meier survival graphs were constructed, and a log-rank comparison of 
the groups was used to calculate p values. Unpaired t test was used for comparison of 
experimental groups. Differences were considered to be significant for p ≤ 0.05. Prism 
software was used for data analysis and drawing graphs (GraphPad). Data represent mean ± 
SEM.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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In Brief
Azzi et al. show the targeted delivery of microparticles containing tacrolimus to the 
draining lymph nodes of recipients following organ transplantation via intravenous 
administration. Microparticles containing tacrolimus coated with an antibody against 
peripheral lymph node addressin are trafficked to the draining lymph nodes, resulting in a 
significant prolongation of murine heart allograft survival.
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Highlights
• The MECA79 antibody binds peripheral lymph node addressin (PNAd)
• Tacrolimus-loaded microparticles coated with MECA79 target lymph 
nodes
• Microparticles accumulate in draining lymph nodes after intravenous 
delivery
• Targeted delivery of tacrolimus prolonged allograft survival
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Figure 1. Preparation of TAC-PLA Polymer Conjugate and Formulation of PEGylated MP-TAC-
MECA79 and MP-TAC
(A) Schematic of the synthesis of TAC-PLA polymer conjugate by means of TAC-initiated 
LA polymerization in the presence of (BDI-EI)ZnN(TMS)2 catalyst and preparation of MP-
TAC-MECA79 with the surface modified by the MECA79 antibody.
(B) FT-IR spectra of LA (red) and TAC-PLA conjugates (blue). The complete conversion of 
LA was determined via FT-IR by monitoring the disappearance of the band at 1772 cm−1).
(C) MALDI-TOF analysis for TAC-PLAn conjugates. The obtained mass to charge ratio 
(m/z) is identical to the calculated m/z of [TAC-PLAn + Na]+ (804.0+143.9 × n + 23).
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Figure 2. Characterization of PEGylated MP-TAC-MECA79 and MP-TAC
(A) DLS measurement of MP-TAC-MECA79. D, average diameter; PDI, polydispersity 
index.
(B) A representative scanning electron microscope image of PEGylated MP-TAC-MECA79 
(scale bar, 1 µm).
(C) Formulation parameters and physicochemical properties of PEGylated MP-TAC-
MECA79 and MP-TAC. Mw PEG, molecular weight of poly(ethylene glycol.
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(D) Particle sizes and polydispersities of MP-TAC-MECA79 and MP-TAC before and after 
lyophilization.
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Figure 3. MP-TAC-MECA79 Suppresses T Cell Proliferation in a Dose-Dependent Fashion In 
Vitro and Suppresses Inflammatory Cytokine Production by T Cells
(A) C57BL/6 splenocytes were stimulated in vitro with anti-CD3 and anti-CD28 antibodies 
in a flat-bottom plate. MP-TAC-MECA79 was added in escalating doses to the T cell 
stimulation assay. MP-TAC-MECA79 suppressed T cell proliferation, as measured by 
thymidine incorporation, in a dose-dependent fashion, starting at 0.5 ng/ml TAC-equivalent 
concentration (*p < 0.05). Ctrl, control, CPM, count per minute.
(B) Free TAC suppressed T cell proliferation, as measured by thymidine incorporation, in a 
dose-dependent fashion, starting at 0.5 ng/ml TAC-equivalent concentration (*p < 0.05).
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(C) The suppression of IL2 production by CD3/CD28-stimulated T cells by MP-TAC-
MECA79 at a concentration of 1 ng/ml TAC equivalent (*p < 0.05).
(D) The suppression of IFNγ production by CD3/CD28-stimulated T cells by MP-TAC-
MECA79 at a concentration of 1 ng/ml TAC equivalent (*p < 0.05).
(E) The suppression of IL6 production by CD3/CD28-stimulated T cells by MP-TAC-
MECA79 at a concentration of 1 ng/ml TAC equivalent (*p < 0.05).
(F) The suppression of IL17 production by CD3/CD28-stimulated T cells by MP-TAC-
MECA79 at a concentration of 1 ng/ml TAC equivalent (*p < 0.05).
Azzi et al. Page 23
Cell Rep. Author manuscript; available in PMC 2017 May 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. Increased Expression of PNAd in DLNs Facilitates Targeted Delivery of MP-MECA79 
in a Transplant Mouse Model
(A) Western blot analysis of cell suspensions from the DLNs of mice transplanted with 
syngeneic or allogeneic skin grafts showed a 4-fold increase in PNAd expression in 
allogeneic compared with syngeneic transplants. Total ERK1 was used as a loading control. 
The fold change over the syngeneic sample was calculated after densitometric analysis and 
correction for ERK1 (***p < 0.001).
(B) Western blot analysis of cell suspensions from the DLNs and non-DLNs of mice 
transplanted with allogeneic skin grafts showed significant increases in PNAd expression in 
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DLNs compared with non-DLNs. The fold change over the non-DLN sample was calculated 
after densitometric analysis and correction for ERK1 (*p < 0.05).
(C) DLNs of mice transplanted with allogeneic skin grafts were analyzed by 
immunohistochemistry after intravenous injection of rhodamine-labeled MP-TAC-MECA79 
(MP-Rhd-MECA79) or MP-TAC (MP-Rhd). DLN showed greatly increased PNAd (arrows) 
compared with non-draining LNs (pancreatic LNs). A 20× objective was used. Further 
extension of PNAd-positive cells from much larger vessels in the DLNs was also observed 
(left). A 40× objective was used.
(D) MECA79 particles but not control particles are localized to adjacent spaces of PNAd-
positive endothelial cells in the DLNs. Many MECA79 particles are lined up by PNAd. The 
cell nuclei were visualized by DAPI. A 40× objective was used.
(E) A higher number of particles was counted per high-power field (200×) in DLNs isolated 
from mice treated with MP-Rhd-MECA79 compared with MP-Rhd (*p < 0.05, n = 4 mice/
group).
(F) Two-photon imaging shows greatly increased PNAd expression (green) in DLNs 
compared with non-draining LNs. A higher number of MP-Rhd-MECA79 is observed in the 
DLNs compared with the non-draining LNs.
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Figure 5. Blocking PNAd Reduces Targeted Delivery of MP-MECA79 in a Transplant Mouse 
Model
(A) FACS analysis of cell suspension from the inguinal DLNs of skin transplant recipients 
injected with either MP-Rhd-MECA79 or MP-Rhd, showing a greater accumulation of 
rhodamine-labeled MP-MECA79 compared with MPs.
(B) FACS analysis of cell suspension from the DLNs of skin transplant recipients injected 
with blocking anti-PNAd antibody 1 hr before injection of rhodamine-labeled particles.
(C) The absolute number of rhodamine-labeled particles in the four different groups of mice 
(n = 4 mice /group, *p < 0.05).
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Figure 6. MP-TAC-MECA79 Prolongs Heart Allograft Survival in Mice with Lower Serum Peak 
and Trough TAC Levels Compared with the Free TAC Group
(A) Immunohistochemistry analysis of the DLN of mice transplanted with heart allografts 
showed an increase in PNAd expression compared with non-draining LNs (axillary LNs) on 
day 7 post-transplantation. A 20× objective was used. Further extension of PNAd-positive 
cells from much larger vessels in the DLNs was also observed, giving a mesh-like 
appearance (arrows).
(B) C57BL/6 mouse recipients of fully mismatched BALB/c hearts were injected daily via 
the tail vein with either MP-TAC-MECA79, MP-TAC, MP-MECA79, or free TAC at 1 
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mg/kg TAC equivalent. The TAC level was measured in the peripheral blood of the 
transplanted mice on day 3 after transplantation. The graph shows that the peak TAC level 2 
hr after injection of the compounds was significantly lower for MP-TAC-MECA79 
compared with free TAC (*p < 0.05, n = 4 mice/group).
(C) The TAC trough level 24 hr after injection was significantly lower for MP-TAC-
MECA79 compared with free TAC (*p < 0.05).
(D) Kaplan-Meier survival curve of heart allograft recipients treated with MP-TAC-
MECA79. C57BL/6 mouse recipients of fully mismatched BALB/c hearts were injected 
daily via the tail vein with either MP-TAC-MECA79, MP-TAC, MP, MP-MECA79, or free 
TAC at 1 mg/kg TAC equivalent. Compared with the other groups, treating recipients with 
MP-TAC-MECA79 significantly increased heart allograft survival (median survival 7 versus 
7 versus 7 versus 7 versus 11 days, respectively; n = 4/group; p < 0.05).
(E) FACS analysis of DLNs from heart transplant recipients treated with either MP-TAC-
MECA79, MP-TAC, or free TAC showing a significant reduction in the percentage of 
effector CD4 T cells (CD4+CD62LlowCD44high) in DLNs of mice treated with MP-TAC-
MECA79 compared with the MP-TAC- or free TAC-treated groups.
(F) The absolute count of CD4 effector T cells in the DLNs of the three different groups of 
transplanted mice shows a significantly lower number of CD4 effector T cells in the DLNs 
of mice treated with MP-TAC-MECA79 compared with mice treated with MP-TAC or free 
TAC (*p < 0.05, n = 3–4 mice/group).
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